公司概覽
業務類別 Biotechnology
業務概覽 City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
公司地址 399 Binney Street, Cambridge, MA, USA, 02142
電話號碼 +1 857 357-2024
傳真號碼 --
公司網頁 https://www.citytx.com
員工數量 81
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Keith Regnante Chief Financial Officer -- 24/09/2026
Mr. Tracy Zimmermann Chief Scientific Officer -- 24/09/2026
Mr. Andrew C. Orth President, Chief Executive Officer and Director -- 24/09/2026
Dr. Baisong Mei, M.D. Chief Medical Officer -- 24/09/2026
Dr. Sebastian Trousil, PhD Chief Operating Officer -- 24/09/2026
 
董事會成員
董事會 職務 更新日期
Mr. Barry E. Greene Director 24/09/2026
Dr. John M. Maraganore,PhD Executive Chairman of the Board 24/09/2026
Mr. Robert Taylor Nelsen Director 24/09/2026
Dr. Saraswathy V. Nochur, PhD Director 24/09/2026
Mr. Andrew C. Orth President, Chief Executive Officer and Director 24/09/2026
Mr. Ron Philip Director 24/09/2026
 
所屬ETF (更新日期: 07/11/2026 02:35)
代號 名稱 佔比% ▼ 持有日期
TDNAT. Rowe Price Biotech ETF0.002%31/10/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.